Blonde L, Rosenstock J, Del Prato S, et al. - In patients with T2D receiving daily or weekly glucagon-like peptide 1 receptor agonist (GLP-1 RA) therapy, researchers examined switching to a titratable fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi). This trial comparing switching to iGlarLixi compared with continuing prior GLP-1 RA in patients with T2D and HbA1c 7–9% (53–75 mmol/mol) taking maximum tolerated doses of a GLP-1 RA daily (60% on liraglutide once daily or exenatide twice daily) or weekly (40% on dulaglutide, exenatide extended release, or albiglutide) with metformin with or without pioglitazone and with or without sodium–glucose cotransporter 2 inhibitors. Investigators found that switching to iGlarLixi improves glucose control in patients with T2D who are not adequately controlled at a maximum tolerated dose of GLP-1 RA plus oral antihyperglycemic agents. The rates of nausea and vomiting, as well as the number of documented symptomatic hypoglycemia events per patient-year, were generally low but higher with iGlarLixi vs continued GLP-1 RA therapy.